Buckling up against COVID-19 after CAR T-cell therapy

In this issue of Blood, Atanackovic et al(1) and Oh et al(2) separately report on T-cell immune responses following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccination in patients with non-Hodgkin lymphoma (NHL) receiving CD19 chimeric antigen receptor (CAR) T-cell therapy. Collectively, their findings suggest a potential seatbelt of immune protection against coronavirus disease 2019 (COVID-19) for patients whose treatment journey requires traveling by CD19 CAR T cells.

Automated summary

In this study, the T-cell immune responses following SARS-CoV-2 mRNA vaccination in non-Hodgkin lymphoma patients receiving CD19 CAR T-cell therapy were investigated. The findings suggest that these patients may have immune protection against COVID-19.